BRCA1 c.5096G>A (p.Arg1699Gln)
At the National Cancer Genetics MDT on 16th Sept 2021 and UKCGG council meeting on 21st September 2021, clinical management of carriers of the variant BRCA1 c.5096G>A (p.Arg1699Gln) (R1699Q) was discussed, given that epidemiological studies have shown that the associated risks have been found to be lower than those associated with other pathogenic/likely pathogenic variants in this gene. The agreed national consensus was to follow the management guidelines outlined in the ENIGMA consortium paper (PMID: 28490613)*.
A summary of the recommendations from this paper is outlined below.
For carriers of BRCA1 c.5096G>A (p.Arg1699Gln):
For non-carriers of BRCA1*R1699Q from BRCA1*R1699Q families
Other variants associated with reduced/atypical penetrance
Other variants associated with reduced or atypical penetrance have been reported in BRCA1 and BRCA2 as well as in other cancer predisposition genes. The absence of formal variant-specific epidemiological studies largely precludes generation of specific risk estimates and management guidelines.
Where available evidence suggests a variant is known associated with reduced or atypical penetrance, this should be specified on the laboratory report in line with best practice guidance.
Recommendations for screening and/or risk reducing surgery in carriers of such variants should be individualised, and consider other factors such as personal and family history, and other lifestyle/environmental or co-existing genetic modifiers of disease.
Please see the UKCGG/CStAG statement here below regarding management of carriers of BRCA1 or BRCA2 variants associated with non-standard penetrance.
The identification of constitutional TP53 variants associated with reduced or atypical penetrance presents challenges for clinical interpretation, genetic counselling and management. Existing surveillance and risk-reduction recommendations were largely developed for individuals carrying TP53 variants with standard penetrance and may not apply to all variant carriers.
This UKCGG statement provides pragmatic recommendations to support a more nuanced, variant-informed approach to clinical management. It considers the limitations of current evidence, the importance of variant-specific and individual risk assessment, and the potential implications of applying intensive surveillance recommendations to individuals whose cancer risks may differ substantially from carriers of high/standard risk variants.
The statement aims to promote consistency in clinical practice while recognising the need for individualised decision-making and ongoing review as further evidence emerges.
Loading...